azithromycin

azithromycin is a broad-spectrum macrolide antibiotic utilized in the treatment of various bacterial infections. It is effective against pathogens responsible for respiratory tract infections, skin conditions, and certain sexually transmitted diseases. The drug is distinguished by its extensive tissue distribution and prolonged half-life, allowing for shorter treatment courses. It was developed by the pharmaceutical company Pliva and is widely marketed under the brand name Zithromax.

Medical uses

It is prescribed for community-acquired pneumonia, acute bacterial exacerbations of chronic obstructive pulmonary disease, and streptococcal pharyngitis. It is a first-line agent for uncomplicated genital infections caused by Chlamydia trachomatis and is used in regimens for pelvic inflammatory disease. Off-label, it is employed in the management of Mycobacterium avium complex in patients with advanced HIV infection and as a prophylactic measure in chronic conditions like bronchiectasis. Its use in treating COVID-19 was investigated during the COVID-19 pandemic, though evidence for efficacy was limited.

Adverse effects

Common side effects involve the gastrointestinal system, including nausea, vomiting, diarrhea, and abdominal pain. More serious risks include QT interval prolongation, which can precipitate torsades de pointes, particularly in patients with existing cardiac conditions or those taking other QT-prolonging drugs like fluoroquinolones. Infrequent but severe reactions include hepatotoxicity, Clostridioides difficile-associated diarrhea, and allergic reactions ranging from rash to Stevens–Johnson syndrome. The U.S. Food and Drug Administration has issued warnings regarding potential cardiovascular risks.

Pharmacology

It acts by binding to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis and exhibiting bacteriostatic activity. Its spectrum includes many Gram-positive organisms, some Gram-negative bacteria, and atypical pathogens like Legionella pneumophila. A key pharmacokinetic feature is its extensive uptake by phagocytes and fibroblasts, leading to high concentrations in tissues such as the lung, tonsil, and prostate. Metabolism occurs minimally in the liver via cytochrome P450 enzymes, and it is primarily eliminated unchanged in bile.

History

The discovery was made by researchers at the Croatian company Pliva in 1980, led by Slobodan Đokić. It was approved for medical use in the European Union in 1988 and subsequently in the United States in 1991 after Pfizer secured licensing rights and marketed it as Zithromax. Its development represented a significant advancement over earlier macrolides like erythromycin, offering improved tolerability and a more convenient dosing schedule. The patent dispute between Pliva and Pfizer was a notable event in international pharmaceutical law.

Society and culture

It is on the World Health Organization's List of Essential Medicines and is available as a generic medication, increasing its accessibility globally. High consumption rates, particularly for respiratory infections, have contributed to concerns about antimicrobial resistance, a major focus of the Centers for Disease Control and Prevention. Its use in mass drug administration programs for trachoma control is supported by the World Health Organization. The drug's "Z-Pak" dosing regimen became widely recognized in popular culture, symbolizing convenient antibiotic therapy.

Category:Macrolide antibiotics Category:World Health Organization essential medicines